Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mourad Farouk-Rezk

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Rheumatology (Oxford, England)|September 15, 2017
The road from development to approval: evaluating the body of evidence to confirm biosimilarityPaul Declerck, Mourad Farouk Rezk
Pharmaceutical Research|September 19, 2015
Biosimilarity Versus Manufacturing Change: Two Distinct ConceptsPaul Declerck, Mourad Farouk-Rezk, Pauline M Rudd
Rheumatology and Therapy|November 7, 2016
Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in EuropeKunal Thakur, Anna Biberger, Alexandra Handrich, et al.
Rheumatology and Therapy|October 18, 2016
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali<sup>®</sup>) Versus Etanercept (Enbrel<sup>®</sup>) - Findings from a Nurse Survey in EuropeKunal Thakur, Anna Biberger, Alexandra Handrich, et al.
Clinical and Experimental Rheumatology|July 15, 2020
BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritisCarlo Selmi, Klaus Krüger, Alain Cantagrel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 12, 2020
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab BiosimilarsHans C Ebbers, Bjørn Fehrmann, Mette Ottosen, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Rheumatology (Oxford, England)|September 15, 2017
The road from development to approval: evaluating the body of evidence to confirm biosimilarityPaul Declerck, Mourad Farouk Rezk
Pharmaceutical Research|September 19, 2015
Biosimilarity Versus Manufacturing Change: Two Distinct ConceptsPaul Declerck, Mourad Farouk-Rezk, Pauline M Rudd
Rheumatology and Therapy|November 7, 2016
Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in EuropeKunal Thakur, Anna Biberger, Alexandra Handrich, et al.
Rheumatology and Therapy|October 18, 2016
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali<sup>®</sup>) Versus Etanercept (Enbrel<sup>®</sup>) - Findings from a Nurse Survey in EuropeKunal Thakur, Anna Biberger, Alexandra Handrich, et al.
Clinical and Experimental Rheumatology|July 15, 2020
BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritisCarlo Selmi, Klaus Krüger, Alain Cantagrel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 12, 2020
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab BiosimilarsHans C Ebbers, Bjørn Fehrmann, Mette Ottosen, et al.
Pageof 1